Allogeneic hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation has been studied in 38 papers since 2016: 27 observational studies in people, 1 in animals, 6 reviews; 17 in the past year. Its furthest trials in people are at phase 3. The newest paper, Oct 26, 2026: “Molecular Underpinnings and Prevalence of Donor Cell-Derived Hematologic Neoplasms among Spanish Transplantation Centers”.

InterventionPhase 3

38 papers study it19 findingsUpdated

4 new papers in 30 daysSee all 38 papers on allogeneic hematopoietic stem cell transplantation

At a glance

Independent labs found the same change in people. 11 independent labs in 10 countries; 182 trials, none about aging, 31 with no results posted.

“i) an inverse J-shaped hazard in unrelated donor-source t≤100-day; ii) convergence of unrelated-related hazard lines”
AFT survival model to capture the rate of aging and age-specific mortality trajectories among first-allogeneic hematopoietic stem cells transplant patientsPloS one2018doi:10.1371/journal.pone.0193287

None of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 11 independent labs in 10 countries
  • 182 trials, none about aging, 31 with no results posted
  • Funders: Børnecancerfonden and others
  • 2 of 18 findings with company ties
  • Humans27
  • Animals1
  • In silico2

What did studies of allogeneic hematopoietic stem cell transplantation find?

10

Studies of allogeneic hematopoietic stem cell transplantation measured 10 outcomes, among them clonal hematopoiesis of indeterminate potential, infection burden and quality of life.

Clonal hematopoiesis of indeterminate potential

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with higher clonal hematopoiesis of indeterminate potential in recipients with SCD.

    “After HCT, the proportion of recipients with SCD with CH increased, driven primarily by mutations in DNMT3A/TET2 and TP53”

    Humansin recipients with SCDnonmyeloablative transplantwhole bloodn = 98

    Characteristics of donor and recipient clonal hematopoiesis in nonmyeloablative transplant for sickle cell disease

    Blood

More on Clonal hematopoiesis of indeterminate potential

Infection burden

downin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with lower infection burden in humans (STAT3-HIES).

    “allogeneic hematopoietic stem cell transplantation was performed and showed reduction in infection burden.”

    HumansSTAT3-HIESn = 6

    Clinical features, genetics, treatment, and long-term outcomes of STAT3 hyper-IgE syndrome: Single-center cohort analysis

    The Journal of allergy and clinical immunology

Quality of life

no changein humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation was not clearly linked with quality of life in humans (versus biological siblings) (PH median 49.9 vs 50.7 (P = .77), MH median 50.9 vs 51.6 (P = .58)).

    “PH and MH-related QoL of recipients was similar to that of siblings”

    Humansversus biological siblings

    Quality of Life and Comorbidities of Long-Term Survivors of Allogeneic Hematopoietic Cell Transplant Versus Their Siblings

    Transplantation and cellular therapy

VEXAS syndrome

downin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation decreases VEXAS syndrome in humans.

    “Even though allogeneic hematopoietic stem cell transplantation (HSCT) remains the sole option for a cure”

    Review

    Bone marrow vacuolization to curative strategies: Evolving paradigms in VEXAS syndrome management

    Current research in translational medicine

More on VEXAS syndrome

Telomere length

downin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with lower telomere length in humans (post-transplantation).

    “Telomere length analysis also revealed accelerated shortening in transplanted cells”

    Humanspost-transplantationn = 21

    Influence of the Bone Marrow Microenvironment on Hematopoietic Stem Cell Behavior Post-Allogeneic Transplantation: Development of Clonal Hematopoiesis and Telomere Dynamics

    International journal of molecular sciences

More on Telomere length

Gait speed

no changein humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation was not clearly linked with gait speed in humans.

    “However, mobility and gait speed were not affected on a group level.”

    Humansmalesn = 98

    Physical Fitness and Frailty in Males after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Long-Term Follow-Up Study

    Cancers

Frailty

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with higher frailty in humans (pre-frail 20% or frail 10%).

    “The prevalence of frailty (pre-frail 20% or frail 10%) was high among the survivors.”

    Humansmalesn = 98

    Physical Fitness and Frailty in Males after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Long-Term Follow-Up Study

    Cancers

Muscle strength

downin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with worse muscle strength in humans (median Z-score -0.7).

    “Survivors presented significantly lower muscle strength and muscle endurance in the dominant hand-grip strength (median Z-score -0.7, range -4.3-3.9) and sit-to-stand tests”

    Humansmalesn = 98

    Physical Fitness and Frailty in Males after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Long-Term Follow-Up Study

    Cancers

Physiological reserve

downin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with worse physiological reserve in humans (markedly reduced).

    “Physiological reserve was markedly reduced in transplant survivors, reflected by 6 min walk test.”

    Humansn = 26

    Premature ageing following allogeneic hematopoietic stem cell transplantation

    Bone marrow transplantation

Epigenetic age

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with higher epigenetic age in humans (donor blood cells in recipients compared with the same cells in donors).

    “the measured age of donor blood cells was significantly higher than these blood cells residing in their respective donors”

    Humansdonor blood cells in recipients compared with the same cells in donorsbloodn = 26

    Premature ageing following allogeneic hematopoietic stem cell transplantation

    Bone marrow transplantation

More on Epigenetic age

What is allogeneic hematopoietic stem cell transplantation linked with?

9

Studies link allogeneic hematopoietic stem cell transplantation with 9 measures, among them donor cell-derived hematologic neoplasm, donor-lineage affiliation and overall survival.

Donor cell-derived hematologic neoplasm

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is associated with donor cell-derived hematologic neoplasm in humans (compared with unrelated-donor transplantation) (0.41% vs. 0.06%; p=0.0026).

    “with a marked predominance after related-donor compared with unrelated transplantation (0.41% vs. 0.06%, p=0.0026).”

    Humanscompared with unrelated-donor transplantationrelated-donorn = 8,465

    Molecular Underpinnings and Prevalence of Donor Cell-Derived Hematologic Neoplasms among Spanish Transplantation Centers

    Blood

More on Donor cell-derived hematologic neoplasm

Donor-lineage affiliation

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is associated with donor-lineage affiliation in humans under a score-pairing null.

    “After allogeneic haematopoietic stem-cell transplantation, recipient-blood scores showed excess donor-lineage affiliation under a score-pairing null.”

    Humansunder a score-pairing nullblood

    Chronological age prediction does not prove biological age measurement

    bioRxivPreprint

Overall survival

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is associated with overall survival in humans (Severe aplastic anemia; compared with HLA-matched sibling donors aged ≥50 years).

    “recipients of haploidentical grafts from younger donors achieved superior OS and FFS compared with those transplanted from older HLA-matched sibling donors.”

    HumansSevere aplastic anemia; compared with HLA-matched sibling donors aged ≥50 yearshaploidentical graft from a donor aged <50 years

    Who is the best allogeneic hematopoietic stem cell transplant donor for severe aplastic anemia? Data from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)

    Science bulletin

Donor-derived myeloid neoplasm

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is associated with donor-derived myeloid neoplasm in humans (Suspected donor origin; definitive demonstration was not possible).

    “This case represents a suspected donor-derived myeloid neoplasm arising after allo-HSCT”

    HumansSuspected donor origin; definitive demonstration was not possiblebone marrowfemales

    Suspected Donor-derived Myeloid Neoplasia After Allogeneic HSCT: A Case-based Review of Clonal Evolution

    In vivo (Athens, Greece)

More on Donor-derived myeloid neoplasm

Comorbidity

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with a higher risk of comorbidity in humans (versus biological siblings) (51.9% vs 33.1% (P = .002)).

    “The 106 recipients experienced significantly more comorbidities versus their siblings”

    Humansversus biological siblings

    Quality of Life and Comorbidities of Long-Term Survivors of Allogeneic Hematopoietic Cell Transplant Versus Their Siblings

    Transplantation and cellular therapy

More on Comorbidity

Clonal hematopoiesis of indeterminate potential

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with a higher risk of clonal hematopoiesis of indeterminate potential in humans (post-transplantation).

    “Compared to age-matched healthy controls, recipients showed a significantly higher incidence of CH”

    Humanspost-transplantationn = 21

    Influence of the Bone Marrow Microenvironment on Hematopoietic Stem Cell Behavior Post-Allogeneic Transplantation: Development of Clonal Hematopoiesis and Telomere Dynamics

    International journal of molecular sciences

More on Clonal hematopoiesis of indeterminate potential

Biological age

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is associated with biological age in humans.

    “These clinical and biological observations suggest that allogeneic HCT is associated with accelerated ageing.”

    Humansn = 26

    Premature ageing following allogeneic hematopoietic stem cell transplantation

    Bone marrow transplantation

Age-specific mortality trajectories

mixedin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is associated with age-specific mortality trajectories in humans (By donor source and post-transplant time-lapse interval).

    “i) an inverse J-shaped hazard in unrelated donor-source t≤100-day; ii) convergence of unrelated-related hazard lines”

    HumansBy donor source and post-transplant time-lapse intervalfirst-allogeneicn = 11,160

    AFT survival model to capture the rate of aging and age-specific mortality trajectories among first-allogeneic hematopoietic stem cells transplant patients

    PloS one

Blood methylation-predicted age

downin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is associated with blood methylation-predicted age in humans (recipients compared with their respective donors) (3.7 years lower than donor predicted age; p = 7.8 × 10(-4)).

    “the predicted age of a recipient was consistently lower than the predicted age of a donor by 3.7 years (p = 7.8 × 10(-4)).”

    Humansrecipients compared with their respective donorswhole blood27–360 days after HSCTn = 16

    Donor age and C1orf132/MIR29B2C determine age-related methylation signature of blood after allogeneic hematopoietic stem cell transplantation

    Clinical epigenetics

More on Blood methylation-predicted age

Has allogeneic hematopoietic stem cell transplantation been tested in people?

0 of 182 about aging

Yes: 27 observational studies in people have been published, and 182 trials are registered.

In trials

40 of 87

Stopped

  • NCT00920153TerminatedHodgkin lymphoma

    Other new drugs

  • NCT00589602TerminatedMultiple myeloma

    slow accrual

  • NCT00698685TerminatedMultiple myeloma

    Pentostatin/alemtuzumab regimen had greater risk of graft failure.

  • NCT01116232TerminatedMultiple myeloma

    Lack of funding.

  • NCT01534143TerminatedMultiple myeloma

    Data was not collected, because funding was unavailable to continue study.

  • NCT03246906TerminatedMultiple myeloma

    Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.

All 17

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 4Feb 2026: 0Mar 2026: 1Apr 2026: 1May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 1Sep 2026: 4Oct 2026: 3Nov 2026: 016 papers in 12 months
bioRxiv

Chronological age prediction does not prove biological age measurement

Researchers show that standard age-trained clocks reflect task-specific statistics rather than true biological aging constructs, limiting how researchers interpret clock…Researchers show that standard age-trained clocks reflect task-specific statistics rather than true biological aging constructs, limiting how researchers interpret clock gaps and rejuvenation.

Preprint: computational studyBiomarkers
International Journal of Molecular Sciences

Donor TET2 variant linked to lower stem cell transplant survival

Recipients whose donors carried a TET2 Leu1721Trp variant lived a median of 14.3 months compared with 50.8 months for those with wild-type donors.Recipients whose donors carried a TET2 Leu1721Trp variant lived a median of 14.3 months compared with 50.8 months for those with wild-type donors.

Case series of 20 peopleMechanisms

See all 38 papers on allogeneic hematopoietic stem cell transplantation